Valuation : Nutriband Inc.

Market Cap 84.6M 72.89M 69.02M 62.56M 117M 8.08B 118M 820M 315M 4.11B 318M 311M 12.99B P/E 2025
-8.39x
P/E 2026 -1.86x
Enterprise Value 80.27M 69.16M 65.49M 59.36M 111M 7.67B 112M 778M 299M 3.9B 301M 295M 12.33B EV / Sales 2025
41.1x
EV / Sales 2026 26.5x
Free-Float
43.12%
Yield 2025 *
-
Yield 2026 -
1 day-1.80%
1 week+16.58%
Current month+59.38%
1 month+118.87%
3 months+97.73%
6 months+76.87%
Current year+53.30%
1 week 5.46
Extreme 5.46
6.97
1 month 3.09
Extreme 3.09
6.97
Current year 2.8
Extreme 2.8
6.97
1 year 2.8
Extreme 2.8
8.63
3 years 1.53
Extreme 1.53
11.78
5 years 1.53
Extreme 1.53
11.78
10 years 0.86
Extreme 0.857142
43.54
Manager TitleAgeSince
Chief Executive Officer 35 2015-12-31
Chief Executive Officer 52 -
Director of Finance/CFO 77 2020-09-01
Director TitleAgeSince
Chairman 52 2022-01-20
Director/Board Member 48 2018-06-30
Director/Board Member 38 2018-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
1/31/25 Other

Founder

126,833 1.1420%
1/31/25 Option

Chief Financial Officer

212,837 1.9164%
3/20/24 Free

Chief Financial Officer

162,500 2.0745%
Change 5-day change 1-year change 3-year change Capi.($)
+14.47%+16.58%+0.43%+144.21% 73.91M
-1.36%-5.89%-23.14%-0.49% 179B
-0.72%-3.41%-3.49%+11.74% 117B
+0.19%-2.83%+6.20%+80.93% 61.25B
-1.92%-6.01%+8.80%+41.11% 50.24B
+0.81%-3.73%-6.67%-33.43% 48.05B
-1.75%-5.54%+9.25%-22.61% 31.89B
+0.43%-11.10% - - 28.42B
+0.58%+1.84%+31.28%-12.82% 24.23B
+0.49%-7.65%-12.44%+4.86% 21.4B
Average -0.50%-3.03%+1.14%+23.72% 56.16B
Weighted average by Cap. -0.70%-4.91%-6.12%+10.85%

Financials

2025 2026
Net sales 2.14M 1.84M 1.75M 1.58M 2.97M 204M 2.98M 20.73M 7.97M 104M 8.04M 7.86M 329M 2.04M 1.75M 1.66M 1.51M 2.83M 195M 2.84M 19.73M 7.59M 98.99M 7.65M 7.48M 313M
Net income -10.48M -9.03M -8.55M -7.75M -14.54M -1B -14.62M -102M -39.06M -509M -39.37M -38.5M -1.61B -8.23M -7.09M -6.71M -6.09M -11.42M -786M -11.47M -79.74M -30.66M -400M -30.91M -30.23M -1.26B
Net Debt -4.13M -3.55M -3.37M -3.05M -5.72M -394M -5.75M -39.97M -15.37M -201M -15.49M -15.15M -634M -4.33M -3.73M -3.53M -3.2M -6.01M -414M -6.04M -41.95M -16.13M -210M -16.26M -15.9M -665M
Logo Nutriband Inc.
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Employees
-
Date Price Change Volume
26-09-11 US$6.960 +14.47% 99,140
26-09-10 US$6.080 +4.83% 112,107
26-09-09 US$5.800 -4.92% 39,044
26-09-08 US$6.100 +2.18% 109,694
26-09-04 US$5.970 +6.04% 96,192
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.960USD
Average target price
15.00USD
Spread / Average Target
+115.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRB Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!